These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Small-molecule nociceptin receptor agonist ameliorates mast cell activation and pain in sickle mice. Vang D; Paul JA; Nguyen J; Tran H; Vincent L; Yasuda D; Zaveri NT; Gupta K Haematologica; 2015 Dec; 100(12):1517-25. PubMed ID: 26294734 [TBL] [Abstract][Full Text] [Related]
9. Cannabinoid receptor-specific mechanisms to alleviate pain in sickle cell anemia via inhibition of mast cell activation and neurogenic inflammation. Vincent L; Vang D; Nguyen J; Benson B; Lei J; Gupta K Haematologica; 2016 May; 101(5):566-77. PubMed ID: 26703965 [TBL] [Abstract][Full Text] [Related]
10. Heme Causes Pain in Sickle Mice Lei J; Paul J; Wang Y; Gupta M; Vang D; Thompson S; Jha R; Nguyen J; Valverde Y; Lamarre Y; Jones MK; Gupta K Antioxid Redox Signal; 2021 Feb; 34(4):279-293. PubMed ID: 32729340 [No Abstract] [Full Text] [Related]
11. Morphine for the treatment of pain in sickle cell disease. Gupta M; Msambichaka L; Ballas SK; Gupta K ScientificWorldJournal; 2015; 2015():540154. PubMed ID: 25654130 [TBL] [Abstract][Full Text] [Related]
12. Pathophysiology of Sickle Cell Disease. Sundd P; Gladwin MT; Novelli EM Annu Rev Pathol; 2019 Jan; 14():263-292. PubMed ID: 30332562 [TBL] [Abstract][Full Text] [Related]
13. State of the Art Management of Acute Vaso-occlusive Pain in Sickle Cell Disease. Puri L; Nottage KA; Hankins JS; Anghelescu DL Paediatr Drugs; 2018 Feb; 20(1):29-42. PubMed ID: 28853040 [TBL] [Abstract][Full Text] [Related]
14. Comprehensive, integrative management of pain for patients with sickle-cell disease. Yoon SL; Black S J Altern Complement Med; 2006 Dec; 12(10):995-1001. PubMed ID: 17212571 [TBL] [Abstract][Full Text] [Related]
15. Pathological pain and the neuroimmune interface. Grace PM; Hutchinson MR; Maier SF; Watkins LR Nat Rev Immunol; 2014 Apr; 14(4):217-31. PubMed ID: 24577438 [TBL] [Abstract][Full Text] [Related]
16. Neuroimmune activation and neuroinflammation in chronic pain and opioid tolerance/hyperalgesia. DeLeo JA; Tanga FY; Tawfik VL Neuroscientist; 2004 Feb; 10(1):40-52. PubMed ID: 14987447 [TBL] [Abstract][Full Text] [Related]
17. Integrative approaches to treating pain in sickle cell disease: Pre-clinical and clinical evidence. Sagi V; Argueta DA; Kiven S; Gupta K Complement Ther Med; 2020 Jun; 51():102394. PubMed ID: 32507420 [TBL] [Abstract][Full Text] [Related]
18. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Yawn BP; Buchanan GR; Afenyi-Annan AN; Ballas SK; Hassell KL; James AH; Jordan L; Lanzkron SM; Lottenberg R; Savage WJ; Tanabe PJ; Ware RE; Murad MH; Goldsmith JC; Ortiz E; Fulwood R; Horton A; John-Sowah J JAMA; 2014 Sep; 312(10):1033-48. PubMed ID: 25203083 [TBL] [Abstract][Full Text] [Related]
19. Understanding the causes of problematic pain management in sickle cell disease: evidence that pseudoaddiction plays a more important role than genuine analgesic dependence. Elander J; Lusher J; Bevan D; Telfer P; Burton B J Pain Symptom Manage; 2004 Feb; 27(2):156-69. PubMed ID: 15157040 [TBL] [Abstract][Full Text] [Related]
20. New and emerging treatments for vaso-occlusive pain in sickle cell disease. Dampier C Expert Rev Hematol; 2019 Oct; 12(10):857-872. PubMed ID: 31364883 [No Abstract] [Full Text] [Related] [Next] [New Search]